Evidence map›Paper›PMID 27364997›Full record

ReviewDiabetologia2016

Coming of age: the artificial pancreas for type 1 diabetes.

Hood Thabit, Roman Hovorka

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04509362 (An 8-Day Initiation Protocol of Advanced Hybrid Closed Loop System In Children and Adolescents With Diabetes Type 1 On Multiple Daily Insulin Injection), which is not on this map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
26.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04509362 completednot on this mapstarted 2020, after this paper: background citation

An 8-Day Initiation Protocol of Advanced Hybrid Closed Loop System In Children and Adolescents With Diabetes Type 1 On Multiple Daily Insulin Injection

TypeobservationalSponsorSidra MedicineRan2020 to 2021Enrolled34ConditionsType 1 DiabetesArmsAdvanced Hybrid Closed Loop System
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 211 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Bolusing frequency and amount impacts glucose control during hybrid closed-loop.Diabetic medicine : a journal of the British Diabetic Association · 2018
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Hood ThabitWellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Level 4, Institute of Metabolic Science, Box 289, Addenbrooke's Hospital, Hills Rd, Cambridge, CB2 0QQ, UK.
Roman HovorkaWellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Level 4, Institute of Metabolic Science, Box 289, Addenbrooke's Hospital, Hills Rd, Cambridge, CB2 0QQ, UK. rh347@cam.ac.uk.
Wellcome/MRC Institute of Metabolic Science · GBWellcome Trust · GB

Funding

One year day-and-night home closed loop in young people with type 1 diabetesUC4DK108520 · NIDDK · UNIVERSITY OF CAMBRIDGE · PI BERGENSTAL, RICHARD MAURITZ, BUCKINGHAM, BRUCE A · 2015 to 2015
$6.3M
Department of Health EME/14/23/09Diabetes UK 07/0003549Medical Research Council MC_PC_12012NIDDK NIH HHS UC4 DK108520
6 · The paper itself

Abstract

The artificial pancreas (closed-loop system) addresses the unmet clinical need for improved glucose control whilst reducing the burden of diabetes self-care in type 1 diabetes. Glucose-responsive insulin delivery above and below a preset insulin amount informed by sensor glucose readings differentiates closed-loop systems from conventional, threshold-suspend and predictive-suspend insulin pump therapy. Insulin requirements in type 1 diabetes can vary between one-third-threefold on a daily basis. Closed-loop systems accommodate these variations and mitigate the risk of hypoglycaemia associated with tight glucose control. In this review we focus on the progress being made in the development and evaluation of closed-loop systems in outpatient settings. Randomised transitional studies have shown feasibility and efficacy of closed-loop systems under supervision or remote monitoring. Closed-loop application during free-living, unsupervised conditions by children, adolescents and adults compared with sensor-augmented pumps have shown improved glucose outcomes, reduced hypoglycaemia and positive user acceptance. Innovative approaches to enhance closed-loop performance are discussed and we also present the outlook and strategies used to ease clinical adoption of closed-loop systems.

Indexed as

Pancreas, ArtificialAlgorithmsBlood GlucoseDiabetes Mellitus, Type 1HumansInsulinBlood GlucoseInsulinArtificial pancreasClosed-loop systemContinuous glucose monitorControl algorithmInsulin pumpReviewType 1 diabetes

Identifiers

PMID27364997
PMCPMC4969330
OpenAlexW2470196169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.